UNASSIGNED: Consecutive patients who underwent curative resection for PDAC (2011-21) and consented to data and tissue collection (Barts Pancreas Tissue Bank) were followed up until May 2023. Clinico-pathological variables were analysed using Cox proportional hazards model.
UNASSIGNED: Of 91 people (42 males [46%]; median age, 71 years [range, 43-86 years]) with a median follow-up of 51 months (95% confidence intervals [CIs], 40-61 months), the recurrence rate was 72.5% (n = 66; 12 loco-regional alone, 11 liver alone, 5 lung alone, 3 peritoneal alone, 29 simultaneous loco-regional and distant metastases, and 6 multi-focal distant metastases at first recurrence diagnosis). The median time to recurrence was 8.5 months (95% CI, 6.6-10.5 months). Median survival after recurrence was 5.8 months (95% CI, 4.2-7.3 months). Stratification by recurrence location revealed significant differences in time to recurrence between loco-regional only recurrence (median, 13.6 months; 95% CI, 11.7-15.5 months) and simultaneous loco-regional with distant recurrence (median, 7.5 months; 95% CI, 4.6-10.4 months; p = 0.02, pairwise log-rank test). Significant predictors for recurrence were systemic inflammation index (SII) ≥ 500 (hazard ratio [HR], 4.5; 95% CI, 1.4-14.3), lymph node ratio ≥ 0.33 (HR, 2.8; 95% CI, 1.4-5.8), and adjuvant chemotherapy (HR, 0.4; 95% CI, 0.2-0.7).
UNASSIGNED: Timing to loco-regional only recurrence was significantly longer than simultaneous loco-regional with distant recurrence. Significant predictors for recurrence were SII, lymph node ration, and adjuvant chemotherapy.
■连续接受PDAC治疗(2011-21)并同意数据和组织收集(Barts胰腺组织库)的患者随访至2023年5月。使用Cox比例风险模型分析临床病理变量。
■91人(42名男性[46%];中位年龄,71年[范围,43-86岁]),中位随访时间为51个月(95%置信区间[CI],40-61个月),复发率为72.5%(n=66;12个局部区域,11只肝脏,5单肺,3单独腹膜,29同时发生局部区域和远处转移,和6个首次复发诊断时的多灶性远处转移)。中位复发时间为8.5个月(95%CI,6.6-10.5个月)。复发后中位生存期为5.8个月(95%CI,4.2-7.3个月)。按复发位置进行分层显示,仅在局部区域复发之间的复发时间存在显着差异(中位数,13.6个月;95%CI,11.7-15.5个月)和同时发生局部区域并伴有远处复发(中位数,7.5个月;95%CI,4.6-10.4个月;p=0.02,成对对数秩检验)。复发的重要预测因素是全身炎症指数(SII)≥500(风险比[HR],4.5;95%CI,1.4-14.3),淋巴结比率≥0.33(HR,2.8;95%CI,1.4-5.8),和辅助化疗(HR,0.4;95%CI,0.2-0.7)。
■仅局部复发的时间明显长于同时局部复发和远处复发的时间。复发的重要预测因素是SII,淋巴结定量,和辅助化疗。